Role of Biologics and Future Perspectives in the Treatment of Urticaria
Author:
- 23 September 2017
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 4 (4) , 428-437
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticariaJournal of the European Academy of Dermatology and Venereology, 2017
- Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trialsJournal of Allergy and Clinical Immunology, 2016
- Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudyJournal of Investigative Dermatology, 2015
- ASSURE‐CSU: a real‐world study of burden of disease in patients with symptomatic chronic spontaneous urticariaClinical and Translational Allergy, 2015
- The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and updateAllergy, 2014
- Chronic Spontaneous UrticariaImmunology and Allergy Clinics of North America, 2014
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Safety and tolerability of omalizumabClinical & Experimental Allergy, 2009
- Development of a Monoclonal Anti-Immunoglobulin E Antibody (Omalizumab) for the Treatment of Allergic Respiratory DisordersAmerican Journal of Respiratory and Critical Care Medicine, 2001